CryoPort Inc (CYRX)

[CYRXorbust]

Thank you sir (or Maam)

the BMS estimates are light in my opinion. one of the products we are going to support is already commercially rolled out. its just a matter of FDA approving cryoport within the protocol. right out the gate that should net CYRX millions alone (general commentary about expected revenues - "and when commercialized, we anticipate $3 million to $20 million-plus annually.") . Then add the fact that they called it one of their "BLOCKBUSTER DRUGS". Novartis ctl019 is by no means a blockbuster drug revenuewise, transformational for sure and a sign of incredible advancements in cell therapies but small potatoes in the grand scheme. "...would lead to $8 to $10 million of global revenues for Cryoport when fully launched" re: CTL019

a "blockbuster" might conservatively generate 2-5x that amount. just don't know how long a bridge study will take. would they need to run a mini Phase 3 trial to validate? if not and we see those #s in 2018, back up the trucks Smith on stocks might be VERY VERY conservative. of course i might be way way off as i usually am.



11/13/16
https://seekingalpha.com/article/4023349-cryoports-cyrx-ceo-jerry-shelton-q2-2017-results-earnings-call-transcript?part=single


So what we’re seeing is we've been asked to support the cryogenic component of one of their biologic blockbuster drugs. But the exact timing of the ramp-up of that support is going to be heavily dependent on us going through their regulatory and quality approval processes. Ultimately there will be - the ramp rate will be dictated by the progress and the expediency that we can move through those processes themselves.
We are actively supporting certain aspects of the program, but it will ramp and additional components will be added as we clear these quality and regulatory hurdles.
Brian Marckx
Mark, when you talk regulatory, is it already FDA-approved?
Mark Sawicki
This product is, but any time you change any support element of an approved or a clinical program, you have to do, what is known as, a bridging study.

Disclaimer: I've been drinking